Delay in Medicare pilot for obesity drugs may not hurt near-term demand, analysts say
By Mariam Sunny
April 22 (Reuters) - A delay in a Medicare pilot to cover obesity drugs due to health insurers' hesitation to participate in the program is unlikely to dent near-term demand for weight-loss treatments, analysts said.
The Centers for Medicare & Medicaid Services told... Read More.
